{
    "name": "nitrofurantoin",
    "comment": "Rx",
    "other_names": [
        "Macrobid",
        "Macrodantin",
        "Furadantin"
    ],
    "classes": [
        "Antibiotics",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/macrobid-macrodantin-nitrofurantoin-342567",
    "pregnancy": {
        "common": [
            "Pregnancy category: B; contraindicated at term",
            "Crosses placenta, but not well distributed",
            "Lactation: Enters breast milk; discontinue drug or do not nurse"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Enters breast milk; discontinue drug or do not nurse"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Renal failure (anuria, oliguria, or CrCl <60 mL/min)",
                "Pregnancy at term (38-42 weeks of gestation)",
                "History of hepatic dysfunction/cholestatic jaundice with nitrofurantoin",
                "Neonates (<28 days)",
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Caution in patients with G6PD deficiency (may increase risk for hemolytic anemia)",
                "Avoid long-term use in the elderly (may increase risk for pulmonary toxicity)",
                "Renal impairment",
                "Discontinue if paresthesia or hemolysis develop",
                "Risk of occasional hepatotoxicity and pulmonary toxicity",
                "Protect from light",
                "Peripheral neuropathy may occur; risk may increase in patients diagnosed with anemia, diabetes, vitamin B deficiency, or electrolyte imbalance (use caution)",
                "Acute/chronic pulmonary reactions (eg., cough, interstitial pneumonitis or fibrosis) reported",
                "Bacterial superinfections may occur with prolonged treatment"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "nitrofurantoin decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "nitrofurantoin, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "darolutamide",
            "description": {
                "common": "darolutamide will increase the level or effect of nitrofurantoin by  Other (see comment). Avoid or Use Alternate Drug. Darolutamide is a BCRP inhibitor. Avoid coadministration with BCRP inhibitors. If use is unavoidable, closely monitor for adverse reactions and consider dose reduction of BCRP substrate drug (refer BCRP substrate prescribing information)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "lasmiditan increases levels of nitrofurantoin by Other (see comment). Avoid or Use Alternate Drug. \nComment: Lasmiditan inhibits BCRP in vitro. Avoid coadministration of lasmiditan with BCRP substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "leniolisib will increase the level or effect of nitrofurantoin by  Other (see comment). Avoid or Use Alternate Drug. Leniolisib, a BCRP inhibitor, may increase systemic exposure of BCRP substrates"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "microbiota oral",
            "description": {
                "common": "nitrofurantoin decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "nitrofurantoin and pexidartinib both increase  Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "nitrofurantoin, pretomanid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selinexor",
            "description": {
                "common": "selinexor, nitrofurantoin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "nitrofurantoin decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib increases levels of nitrofurantoin by Other (see comment). Use Caution/Monitor. \nComment: Acalabrutinib may increase exposure to coadministered BCRP substrates by inhibition of intestinal BCRP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aluminum hydroxide",
            "description": {
                "common": "aluminum hydroxide decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of nitrofurantoin by  increasing elimination. Use Caution/Monitor. Apalutamide weakly induces BCRP and may decrease systemic exposure of drugs that are BCRP substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bazedoxifene/conjugated estrogens",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of bazedoxifene/conjugated estrogens by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupivacaine implant",
            "description": {
                "common": "nitrofurantoin, bupivacaine implant.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Local anesthetics may increase the risk of developing methemoglobinemia when concurrently exposed to drugs that also cause methemoglobinemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "calcium carbonate decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conjugated estrogens",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of conjugated estrogens by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dapsone topical",
            "description": {
                "common": "nitrofurantoin increases toxicity of dapsone topical by altering metabolism. Modify Therapy/Monitor Closely. May induce methemoglobinemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "didanosine",
            "description": {
                "common": "didanosine will increase the level or effect of nitrofurantoin by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Applies to didanosine chewable tablets and powder for oral solution; administer 2 hr before or several hours after didanosine oral solution or chewable tablet administration"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "nitrofurantoin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eluxadoline",
            "description": {
                "common": "eluxadoline increases levels of nitrofurantoin by decreasing metabolism. Use Caution/Monitor. Eluxadoline may increase the systemic exposure of coadministered BCRP substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estradiol",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of estradiol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estrogens conjugated synthetic",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of estrogens conjugated synthetic by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estropipate",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of estropipate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of ethinylestradiol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "fostemsavir will increase the level or effect of nitrofurantoin by  Other (see comment). Modify Therapy/Monitor Closely. Fostemsavir inhibits BCRP transporters. If possible, avoid coadministration or modify dose of BCRP substrate coadministered with fostemsavir."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "glecaprevir/pibrentasvir will increase the level or effect of nitrofurantoin by  decreasing metabolism. Use Caution/Monitor. Glecaprevir/pibrentasvir may increase plasma concentration of BCRP substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mestranol",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of mestranol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mipomersen",
            "description": {
                "common": "mipomersen, nitrofurantoin.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Both drugs have potential to increase hepatic enzymes; monitor LFTs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oteseconazole",
            "description": {
                "common": "oteseconazole will increase the level or effect of nitrofurantoin by  Other (see comment). Modify Therapy/Monitor Closely. Otesezonale, a BCRP inhibitor, may increase the effects and risk of toxicities of BCRP substrates. Use lowest starting dose of BCRP substrate, or consider reducing BCRP substrate dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin",
            "description": {
                "common": "oxybutynin increases levels of nitrofurantoin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin topical",
            "description": {
                "common": "oxybutynin topical increases levels of nitrofurantoin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin transdermal",
            "description": {
                "common": "oxybutynin transdermal increases levels of nitrofurantoin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponatinib",
            "description": {
                "common": "ponatinib increases levels of nitrofurantoin by Other (see comment). Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "regorafenib",
            "description": {
                "common": "regorafenib will increase the level or effect of nitrofurantoin by  Other (see comment). Modify Therapy/Monitor Closely. Regorafenib likely inhibits BCRP (ABCG2) transport. Coadministration with a BCRP substrate may increase systemic exposure to the substrate and related toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "safinamide",
            "description": {
                "common": "safinamide will increase the level or effect of nitrofurantoin by  Other (see comment). Use Caution/Monitor. Safinamide and its major metabolite may inhibit intestinal BCRP. Monitor BCRP substrates for increased pharmacologic or adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium bicarbonate",
            "description": {
                "common": "sodium bicarbonate decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium citrate/citric acid",
            "description": {
                "common": "sodium citrate/citric acid decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium picosulfate/magnesium oxide/anhydrous citric acid",
            "description": {
                "common": "nitrofurantoin decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sofosbuvir/velpatasvir",
            "description": {
                "common": "sofosbuvir/velpatasvir will increase the level or effect of nitrofurantoin by  Other (see comment). Use Caution/Monitor. Velpatasvir is an inhibitor of the drug transporter BCRP. Coadministration may increase systemic exposure of drugs that are BCRP substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol will increase the level or effect of nitrofurantoin by  Other (see comment). Modify Therapy/Monitor Closely. Stiripentol is a BCRP transport inhibitor. Consider dosage reduction for BCRP substrates if adverse effects are experienced when coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tafamidis",
            "description": {
                "common": "tafamidis will increase the level or effect of nitrofurantoin by  Other (see comment). Use Caution/Monitor. Tafamidis inhibits breast cancer resistant protein (BCRP) in vitro and may increase exposure of BCRP substrates following tafamidis or tafamidis meglumine administration. Dosage adjustment of these BCRP substrates may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tafamidis meglumine",
            "description": {
                "common": "tafamidis meglumine will increase the level or effect of nitrofurantoin by  Other (see comment). Use Caution/Monitor. Tafamidis inhibits breast cancer resistant protein (BCRP) in vitro and may increase exposure of BCRP substrates following tafamidis or tafamidis meglumine administration. Dosage adjustment of these BCRP substrates may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetracaine",
            "description": {
                "common": "tetracaine, nitrofurantoin. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimagnesium citrate anhydrous",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of nitrofurantoin; administer nitrofurantoin at least 2 hr before or 6 hr after magnesium; use alternatives if available."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "balsalazide",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of balsalazide by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "biotin",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of biotin by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "didanosine",
            "description": {
                "common": "didanosine, nitrofurantoin.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Enhanced risk of peripheral neuropathy."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib will increase the level or effect of nitrofurantoin by  Other (see comment). Minor/Significance Unknown. Encorafenib (a BCRP inhibitor) may increase the concentration and toxicities of BCRP substrates. Closely monitor for signs and symptoms of increased exposure and consider adjusting the dose of these substrates."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium chloride",
            "description": {
                "common": "magnesium chloride decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium citrate",
            "description": {
                "common": "magnesium citrate decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium hydroxide",
            "description": {
                "common": "magnesium hydroxide decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium oxide",
            "description": {
                "common": "magnesium oxide decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium sulfate",
            "description": {
                "common": "magnesium sulfate decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metoclopramide",
            "description": {
                "common": "metoclopramide decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pantothenic acid",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of pantothenic acid by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pyridoxine",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of pyridoxine by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pyridoxine (Antidote)",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of pyridoxine (Antidote) by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "thiamine",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of thiamine by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Suspected adverse reactions",
            "percent": "1-844"
        },
        {
            "name": "contact Casper Pharma LLC",
            "percent": "5"
        },
        {
            "name": "at",
            "percent": "1-844"
        },
        {
            "name": "CASPER",
            "percent": "522-7737"
        },
        {
            "name": "or FDA at",
            "percent": "1-800"
        },
        {
            "name": "FDA",
            "percent": "1088"
        },
        {
            "name": "or www",
            "percent": null
        },
        {
            "name": "fda",
            "percent": null
        },
        {
            "name": "gov",
            "percent": null
        },
        {
            "name": "medwatch",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Chest pains",
            "percent": null
        },
        {
            "name": "Chills",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Clostridium difficile colitis",
            "percent": null
        },
        {
            "name": "Cyanosis secondary to methemoglobinemia",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Drowsiness",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Exfoliative dermatitis",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Flatulence",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Hemolytic anemia",
            "percent": null
        },
        {
            "name": "Hepatitis",
            "percent": null
        },
        {
            "name": "Increased LFTs",
            "percent": null
        },
        {
            "name": "Itching",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Numbness",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Sore throat",
            "percent": null
        },
        {
            "name": "Stomach upset",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Weakness",
            "percent": null
        },
        {
            "name": "Urine discoloration",
            "percent": null
        },
        {
            "name": "Vasculitis",
            "percent": null
        }
    ]
}